NASDAQ:IXHL News 4 December 2025 - 15 December 2025

Incannex Healthcare Inc. (NASDAQ: IXHL) is back on traders’ radar heading into mid-December, with the stock hovering around $0.42 in early Monday pricing on December 15, 2025, after closing near $0.40 in the prior session. The renewed attention isn’t coming out of nowhere. Over the past several weeks, Incannex has stacked up a series of developments that matter to speculative biotech investors: a U.S. FDA Fast Track designation for its lead obstructive sleep apnea (OSA) program, a Nasdaq minimum bid-price compliance deadline now pushed into 2026, and fresh research commentary from at least one boutique coverage firm—along with a mixed

Incannex Healthcare Inc. (Nasdaq: IXHL) is back on traders’ radar after the U.S. Food and Drug Administration granted Fast Track designation to its lead sleep-apnoea drug candidate, IHL‑42X. The move caps a busy 2025 that also brought strong Phase 2 data in sleep apnoea and psilocybin-assisted therapy, a major clean-up of warrant overhang, and a fight to keep the company’s Nasdaq listing alive. SEC+1 As of the U.S. session on 4 December 2025, IXHL was trading around $0.48 per share, up roughly 8% on the day and extending a sharp two-day rebound following the Fast Track news. ChartMill Below is